Johnson & Johnson (JNJ) Upgraded at Goldman Sachs


The firm currently has a $112.00 price objective on the stock, up from their previous price objective of $102.00. Goldman Sachs' price target indicates a potential upside of 3.41% from the stock's current price.



from Biotech News